N@N

Market Maker Surveillance Report. SBAY, ACAD, CWBS, TRR, XOMA, ELC, Winning Stocks With Lowest Price Friction For Thursday, De

^{Published on 2010-12-23 19:01:49 - WOPRAI}
 

December 23, 2010 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 2625 companies with "abnormal" market making, 2417 companies with positive Friction Factors and 2925 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. SUBAYE INC (NASDAQ:SBAY), ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD), COMMONWEALTH BANKSHARES INC (NASDAQ:CWBS), TRC COS INC (NYSE:TRR), XOMA LTD (NASDAQ:XOMA), EASTERN LIGHT CAPITAL INC (AMEX:ELC). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     SBAY       $2.650       41.09%       366,630         56.11%       261,293         39.99%       105,337         397     
     ACAD       $0.300       27.27%       4,360,556       50.90%       4,206,839       49.10%       153,717         5,124   
     CWBS       $0.250       29.76%       132,691         55.64%       105,699         44.32%       26,992          1,080   
     TRR        $0.800       25.56%       934,696         94.78%       46,253          4.69%        888,443         11,106  
     XOMA       $2.650       58.89%       16,761,450      52.40%       15,081,244      47.15%       1,680,206       6,340   
     ELC        $1.290       33.86%       147,574         56.76%       100,441         38.63%       47,133          365     

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows ELC with a dollar gain Thursday of $1.29000 and a Friction Factor of 365 shares. That means that it only took 365 more shares of buying than selling to move ELC higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

SUBAYE INC (NASDAQ:SBAY) - Subaye, Inc. provides video advertising and entertainment media services to small and medium sized enterprises in China. It operates in three segments: Online Membership Services, Entertainment Media, and Trade Services. The Online Membership Services segment provides online content and member services for commercial use. The Entertainment Media segment produces and places advertising solutions on behalf of its customers and invests in entertainment arts productions. The Trade Services segment provides domestic and international importing and exporting services to acquire and distribute goods within China or internationally. Subaye, Inc. offers SaaS online content management software to manage members online video and graphic showcases and operations within their Webshops at the online shopping mall and to maintain customer data. As of November 30, 2009, the company had 63,311 members. Its video database consisted of 72,126 profiles of corporate video showcases that offer venue for small to mid-size enterprises to advertise their products and services, and establish and enhance their corporate brands. The company was formerly known as MyStarU.com, Inc. and changed its name to Subaye, Inc. in October 2009. Subaye, Inc. was founded in 1997 and is headquartered in Guangzhou, the Peoples Republic of China.

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, focuses on drug discovery and clinical development of novel treatments for central nervous system disorders. The company is developing a portfolio of four product candidates, including pimavanserin, which is being developed for three separate neurological and psychiatric indications in collaboration with Biovail. These indications include Parkinsons disease psychosis that is in Phase III development; adjunctive therapy for schizophrenia, which is in Phase III planning; and Alzheimers disease psychosis, for which ACADIA is planning to initiate a Phase II feasibility study. The company also has other products under development, including a product candidate in Phase II development for chronic pain; and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, as well as a program in IND-track development in collaboration with Meiji Seika Kaisha. The products in ACADIAs pipeline emanate from discoveries made using its proprietary drug discovery platform. The company, formerly known as Receptor Technologies, Inc., was founded in 1993 and is headquartered in San Diego, California.

COMMONWEALTH BANKSHARES INC (NASDAQ:CWBS) - Commonwealth Bankshares, Inc. operates as the holding company for Bank of the Commonwealth, which provides a range of commercial banking services to individuals and small-to medium-sized businesses. The companys deposit product line includes checking and savings deposits, interest bearing demand deposits, and time deposits. Its loan portfolio comprises secured loans, commercial lines of credit, commercial term loans, real estate loans, construction loans, personal loans, home improvement loans, automobile loans, and other installment and term loans. The company also offers other related services, such as home banking, trust, travelers checks, safe deposits, lock box, depositor transfer, customer note payment, collections, notary public, escrow, drive-in facility, and other customary banking services. As of December 31, 2008, it operated four branches in Norfolk; six branches in Virginia Beach; four branches in Chesapeake; two branches in Portsmouth; one branch in Suffolk; and one each branch in Powells Point, Waves, Moyock, and Kitty Hawk, North Carolina. The company, through its other subsidiaries, conducts mortgage funding services; and provides brokerage and investment advisory services, and title insurance services. Commonwealth Bankshares was founded in 1970 and is headquartered in Norfolk, Virginia.

TRC COS INC (NYSE:TRR) - TRC Companies, Inc., through its subsidiaries, provides integrated engineering, consulting, and construction management services in the United States. It operates in three segments: Energy, Environmental, and Infrastructure. The Energy segment provides engineering, licensing, permitting, and construction services to energy companies, including support in the design of new sources of power generation, electrical transmission and distribution system upgrades, and natural gas and liquid products pipelines and terminals. The Environmental segment provides services that focus on building sciences; air quality measurements and modeling; environmental assessment; and environmental remediation services comprising exit strategy, and natural and cultural resource management, as well as RE Power program that offers dismantling, cleanup, liability transfer, and asset optimization solutions to power companies. The Infrastructure segment provides construction management support services in the areas of program management, project management, construction engineering and inspection, plant inspections, estimating, and scheduling; planning, design, and construction management services in support of work on roads, highways, bridges, and aviation facilities; general civil, municipal, and land development engineering services; geotechnical and materials engineering services; hydraulics and hydrological studies; and geographic information systems and mapping services, including data modeling, terrain analysis, shoreline management analysis, total station mapping, and resource mapping. This segment also offers security services, such as vulnerability assessments; engineering and structural improvements for public and private infrastructure facilities; design and implementation of security and surveillance systems; blast resistance design; disaster recovery planning; and force protection analysis. TRC Companies, Inc. was founded in 1969 and is headquartered in Windsor, Connecticut.

XOMA LTD (NASDAQ:XOMA) - XOMA Ltd., incorporated in 1981, is a biopharmaceutical company in the field of therapeutic antibody discovery and development. The Company has a royalty interest in one approved therapeutic antibody, RAPTIVA, which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis. XOMA also has a future royalty interest in additional therapeutic antibody product candidates being developed by others as a result of licensing its technologies. XOMA's pipeline includes both products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. In addition to supporting its product pipeline, the Company uses its infrastructure to provide process development and manufacturing services on a fee-for-service basis.

RAPTIVA (Efalizumab)

The Company markets RAPTIVA under an agreement with Genentech, Inc. as a result of a prior collaborative product development program. RAPTIVA is a humanized therapeutic monoclonal antibody developed to treat immune system disorders. RAPTIVA can be self-administered by patients as a single, once-weekly subcutaneous injection. In 2005, Serono had launched RAPTIVA in over 40 countries worldwide.

RAPTIVA competes with Enbrel from Amgen Inc. and its partner Wyeth Pharmaceuticals; Amevive from Biogen Idec Inc.; BG-12 from Biogen Idec Inc. and Fumapharm AG; Remicade from Centocor, Inc. Humira from Abbott Laboratories, and ISA247 from Isotechnika, Inc.

CHIR-12.12

CHIR-12.12, which is being developed by the Company in collaboration with Chiron Corporation, is an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies. In April 2005, XOMA announced the initiation of Phase I study for patients with advance chronic lymphocytic leukemia (CLL). Then in October 2005, the Company initiated a second Phase I study for patients with multiple myeloma (MM).

NEUPREX (opebacan/rBPI21)

NEUPREX (opebacan/rBPI21) is an injectable formulation of rBPI21, a modified recombinant fragment of human bactericidal/permeability-increasing protein (BPI). BPI is a human host-defense protein made by a type of white blood cell that is involved in the body's defenses against microbial infection. In October of 2003, in conjunction with Children's Medical Center Dallas, the Company announced the initiation of an open-label, single center, dose escalation, investigator-sponsored, Phase I/II clinical trial of NEUPREX in pediatric patients with congenital heart abnormalities requiring open heart surgery associated with cardiopulmonary bypass.

XMA005.2

XMA005.2 is a Human Engineered monoclonal antibody with a high-affinity and potent inhibitory activity against its inflammatory target. This high potency means that it may be suitable for use as a monthly-dose injectable therapeutic. XOMA is evaluating XMA005.2 in preclinical studies targeting multiple indications, including osteoarthritis and rheumatoid arthritis, where less frequent dosing could be a significant marketing advantage.

Anti-gastrin Mab

In September of 2004, XOMA announced a worldwide collaboration with Aphton Corporation to develop treatments for gastrointestinal (GI) and other gastrin-sensitive cancers using anti-gastrin monoclonal antibodies. Gastrin has been shown to be involved in the progression of colorectal, stomach, liver and pancreatic cancers and inhibiting gastrin may inhibit such growth.

Metabolic Disease Target

The Company is co-developing Metabolic Disease Target with Lexicon Genetics. Metabolic Disease Target is a secreted protein involved in metabolic functions such as insulin sensitivity and weight gain that was identified through Lexicon's Knockout Technology. Antibodies to this target may be developed to treat Type II diabetes, obesity and other metabolic diseases.

MLN2222

MLN2222 (also known as CAB2) is being developed by XOMA in partnership with Millennium Pharmaceuticals, Inc. MLN2222 is a complement inhibitor for coronary artery bypass graft surgery tar

EASTERN LIGHT CAPITAL INC (AMEX:ELC) - Eastern Light Capital, Incorporated, a real estate investment trust (REIT), operates as a specialty mortgage finance company in the United States. Its mortgage investment business invests in non-conforming residential mortgage loans. The companys mortgage banking business engages in the origination, purchase, and sale of conforming and non-conforming mortgage loans secured by first liens and junior liens on one-to-four single family residential properties. The company qualifies as a REIT for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as Capital Alliance Income Trust, Ltd and changed its name to Eastern Light Capital, Incorporated in July 2008. Eastern Light Capital was founded in 1995 and is based in San Francisco, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net